-
Nature: Can the accumulation of specific metabolites in aging individuals promote tumor progression?
Time of Update: 2020-09-04
given the growing evidence that the external factors of cancer cells are key to regulating tumor progress, the researchers hypothesically assume that aging may create a systematic environment that supports tumor progress and aggressiveness.
-
TUKYSA (tucatinib) has been approved in Australia for the treatment of metastasis HER2-positive breast cancer.
Time of Update: 2020-09-04
in the United States, TUKYSA's combination with curtum monoantigen and carpedabin was approved for advanced non-excisive or metastasis adult patients with HER2-positive breast cancer, including those with brain metastasis.
-
Nat Commun: Disrupting cognition! Is strong immunity not a good thing? Studies have found that a stronger immune system may block immune treatment for cancer.
Time of Update: 2020-09-04
Researchers at the University of California, San Diego School of Medicine found that tumor cells in patients with strong immunity did not present autoantigen mutations at first, and that major tissue compatible complexes (MHCs) failed to transmit signals to the immune system to "clear cancer cells", thus restricting cancer immunotherapy.
-
Original? Transfer? Remote consultation connects Beijing and Shanghai to solve the tumor mystery.
Time of Update: 2020-09-04
in order to clarify the plan as soon as possible and avoid missing the best time for treatment, the patient's family decided to consult experts in Beijing and issue a consultation request through Shanghai Harmony Hospital.
-
Oral Dis: Oral cancer-related fibroblasts are a risk factor for poor prognosis.
Time of Update: 2020-09-04
high average age and male ratio have significant protective effects .OR 0.940 (95% CI 0.925-9.955), p .lt; 0.001, OR 0.125 (95% CI 0.018-0.867), p .
, the results show that CAFs increase the risk of death, with men in the majority and a higher average age as protective.
-
Lancet Oncol: How much does different treatments and imaging tests affect cancer survival? The Harvard team at The Lancet analyzed data on 11 cancers in 200 countries.
Time of Update: 2020-09-04
, however, even taking into account differences in diagnosis, the five-year net survival rate in high-income areas is much higher, reaching 10-17 times higher in low-income areas in stage I-III cancers.
-
NMPA approves China's first querceton single anti-biosimilar.
Time of Update: 2020-09-04
Fuhong Hanxuan announced that its self-developed quercexal mono-biosimilar HLX02 has been approved for listing by the State Drug Administration (NMPA).
July 27, ZERX02 also received approval from the European Commission (EC), making HLX02 the first "Chinese national" mono-anti-biosimilar to be approved in Europe.
-
New advances in Cancer Cell's oncology resistance research! "Genetic mutations" may not be necessary.
Time of Update: 2020-09-04
This study used genetically engineered mouse models from pre-tumor hyperplision to adenocarcinoma to study changes in single-cell transcription groups of lung adenocarcinoma (LUAD), and found that HPCS was present in tumor cells isolated in both mouse tumors and patients with heterogeneous transplantation, with high differentiation and proliferation capabilities.
-
Nature Genetics: Gao Dong/Chen Lonan and others have identified the potential cell origin of prostate cancer for the first time.
Time of Update: 2020-09-03
the study provides insights into the prostate lineage hierarchy, identifies Dist-Luminal-C cells as a group of cavity progenitocytes, and presents one of the potential cell origins of prostate cancer.
-
BMJ: Older men who love smoking have lost a significant weight in six months, and the risk of cancer has increased significantly.
Time of Update: 2020-09-03
recently published a study in BMJ that quantifies the predicted value of accidental weight loss (WL) for cancer based on the patient's age, sex, smoking status, and clinical characteristics (symptoms, signs, and abnormal blood test results).
-
Science Advances: Liu Zhuang/Yang Kai of Suzhou University has developed a new cancer treatment that is expected to be used in clinical practice.
Time of Update: 2020-09-03
the study has shown that bacteria themselves can act as tumor-specific PTT agents, allowing photoimmune therapy cancer treatment to inhibit tumor metastasis and recurrence.
-
Nat Commun: The hepatocellular nuclei factor 4A regulates the metabolism of thiohampheal and determines the sensitivity of liver cancer to methionine limits.
Time of Update: 2020-09-03
As a sulfur-containing amino acid, methionine is an essential amino acid in the human body and can only be obtained from food, especially animal proteins. have shown that limiting methionine not only
-
Science: Immunotherapy and Microbiology strengthen the immune system to recognize and attack cancer cells.
Time of Update: 2020-09-03
findings, published in the journal Science, suggest that immunotherapy, combined with specific microbial therapies, enhances the immune system's ability to recognize and attack certain melanomas, bladder cancers and colorectal cancer cells.
-
Clin Cancer Res: WEE1 kinase inhibitor adavosertib combined chemotherapy to treat TP53 mutant ovarian cancer.
Time of Update: 2020-09-03
the trial recruited patients with platinum-sensitive ovarian cancer with TP53 mutations to be randomly assigned to the adavosertib group (225 mg, 2/day, oral, 21-day course of medication 2.5 days) or placebo group, all patients received carboptin (AUC5) and yew alcohol (175 mg/m2) until the disease progressed or was 6 courses of treatment.
-
Nat Commun: New developments! Inhibiting the TMBIM6 gene inhibits the growth of primary tumors.
Time of Update: 2020-09-03
In addition, the researchers found that the BIA compound, a potential TMBIM6 antagonist, prevents TMBIM6 from binding to mTORC2, reduces mTORC2 activity, and also regulates the calcium ions leaking from TMBIM6, further inhibiting tumor formation and progression.
-
Science Translational Medicine: Cover article: MIT develops engineered particulate-enhanced tumor immunotherapy.
Time of Update: 2020-09-03
Although local dosing of STING astrologists is expected to be used in cancer immunotherapy, in order to achieve efficacy, the drug treatment program requires months of frequent intra-tumor injections, which can lead to poor patient compliance, and multiple intra-tumor injections can also damage the tumor's microencology and vascular networks, thereby increasing the risk of metastasis.
-
Lancet Glob Health: Why is breast cancer incidence increasing globally and in China?
Time of Update: 2020-09-03
, however, the age-standardized incidence of pre- and post-menovascular breast cancer is highest in countries with very high HDI levels, approximately twice as high as in low- and medium-sized HDI countries.
the highest age-standardized mortality rate for post-menoanthe breast cancer in countries with low and low HDI levels.
-
Nature: Amino acid metabolism changes the regulatory mechanism of tumor suppression.
Time of Update: 2020-09-03
The in vitro study of the metabolic process of amino acids and biosynthetics of esters in non-walled tumor cells, as well as dietary amino acid interventions in HCT116 heterogenous transplant mice, revealed that the lack of serine inhibition of tumors was caused by the mixing of serine palmyl metastase (SPT) and abnormal deoxysphingolipids.
-
First-line treatment of stomach cancer and esophageal cancer! Odivo (Navuliyu monoanti) and chemotherapy programme Phase III clinical data: significantly improved total survival and non-progression survival.
Time of Update: 2020-09-03
results show that Odevo combined chemotherapy will hopefully change the first-line treatment pattern of stomach cancer, gastroesophageal joint cancer or esophageal adenocarcinoma, and become a new standard of treatment for such patients.
-
? Cancer Res: Here's the latest insights into how ovarian cancer is evolving and evolving.
Time of Update: 2020-09-03
researchers have proposed an alternative model of HGSOC discrete subtypes, where tumors develop from an early differentiated spectrum to a late-stage proliferation spectrum along a schedule characterized by genomic instability and the increase in subclonal amplification.
